Efficacy and safe of Ledipasvir/Sofosbuvir with Ribavirin in Patients who failed Daclatasvir/Asunaprevir with chronic hepatitis C-multicenter,pilot study- - Retreatment of Patients who failed DCV/ASV with LDV/SOF+RBV

Hiroshima liver study group0 个研究点目标入组 30 人开始时间: 2016年4月19日最近更新: 2023年10月17日

试验速览

阶段: 2 期
状态: 已完成
发起方
入组人数: 30

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

The overall SVR12 rate was 86.7% (26/30). Large decreases in mean log10 HCV RNA levels were observed in patients without cirrhosis, and the SVR12 rate for these patients was 100% (12/12). In cases of cirrhosis, SVR12 rate was 72.2%(13/18) .The common factors in treatment failure cases were the presence of liver cirrhosis and both NS5A L31M/I and Y93H RAVs. The frequency of RAVs did not change before and after treatment among patients who relapsed.

研究设计

研究类型: Interventional

入排标准

年龄范围: 20years-old 至 ot applicable（—）
性别: All

入选标准

未提供

排除标准

•1)Patients with serious renal disease(eGFR<30mL/min/1.73m2) or dialysis 2)Patients with haemoglobinopathies (thalassemia, sickle cell anemia) 3)Decompenstated liver cirrhosis 4)HCC, malignat tumor 5)Patients with Hb less than 10 g/dl. 6)Pregnant or lactating women and women who may be pregnant 7)Judged by investigator not to be appropriate for inclusion in this study

研究者

发起方

Hiroshima liver study group

相似试验

已完成

2 期

Randomised study assessing efficacy and safety of telaprevir evey 8 or 12 hours with peginterferon alfa 2b and ribavirin in HCV patientsChronic hepatitis C

JPRN-UMIN000006758Hiroshima liver study group50

已完成

不适用

Efficacy and safety of Ledipasvir Plus Sofosbuvir in Patients With Hepatitis C Virus Genotype 2 InfectioPatients With Hepatitis C Virus Genotype 2 Infection

JPRN-UMIN000038604Ogaki Municipal Hospital126

招募中

不适用

Efficacy and safety of Sofosbuvir / Velpatasvir combination therapy for type C decompensated cirrhosistype C decompensated cirrhosis

JPRN-UMIN000038587ippon Medical School, Division of Gastroenterology and Hepatology, Department of Internal Medicine400

已完成

4 期

Sofosbuvir/Ledipasvir for Hepatitis C Genotype 1-6 in Patients With Transfusion-Dependent Thalassemia: An Open Label TrialHepatitis CThalassemia

NCT03032666Ala'a Sharara7

Unknown

4 期

Treatment of Egyptian Hepatitis C Genotype 4 Infected Children and Adolescents With Combined Ledipasvir/SofosbuvirHepatitis C Genotype 4

NCT03743727Yassin Abdelghaffar Charity Center for Liver Disease and Research25